See ratings and reviews when you sign up for an account.

Screening Protocol for Genetic Diseases of Allergic Inflammation and Mast Cell Homeostasis and Activation

This study is currently Recruiting

December 2010 By National Institutes of Health Clinical Center (CC)

First Recieved on February 26, 2009

Last Updated on August 19, 2011

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institutes of Health Clinical Center (CC)
Identifier: NCT00852943


Background: - Mast cells are responsible for most symptoms of allergic reactions. In some allergic diseases, it is unusually easy to cause mast cells to release their contents and cause allergic reactions. In other cases, mast cells grow abnormally and, in rare cases, can result in tumors. Mast cells also control other parts of the immune system. - Understanding why mast cells behave abnormally in allergic diseases is important to finding better ways for diagnosing and treating these potentially life-threatening disorders. Objectives: - To screen mast cells at the genetic and functional levels to characterize abnormalities, identify mutations, detect carrier states, and/or develop therapies for such disorders. - To create a library of information about inherited diseases of mast cell homeostasis and activation, including piebaldism (problems with skin and hair pigmentation), anaphylaxis (severe allergic reaction), allergies, asthma, atopic dermatitis (eczema), allergic rhinitis ( hay fever ), food allergies, urticaria/angioedema (hives/swelling), immunodeficiency diseases, and autoimmune diseases. Eligibility: - Patients between the ages of 1 and 80 years who have been referred by a physician and are known to have or be suspected of having an inherited disorder of mast cells, in particular patients (and their relatives) with piebaldism, allergies, or anaphylaxis that is not caused by allergies. Design: - Study population will consist of up to 250 participants in a 5-year period. One third of the study population will consist of patients; the other two thirds will consist of biological relatives. - Evaluation is limited to testing on blood specimens; no treatment will be provided. - Clinical and research laboratory evaluations of patients will include the following: - Clinical evaluation and previous laboratory tests as documented in outside medical records by health care providers. A standard questionnaire will also be administered at the time of subject enrollment. - Blood collection for clinical laboratory testing, tailored to each subject's clinical evaluation where appropriate (5 ml). - Blood collection for research laboratory testing, tailored to each subject's clinical evaluation-including genetic screening and assessment of mast cell growth and functioning-and storage of additional frozen blood specimens for future studies (up to an additional 30 ml). - Evaluations of bl...

Study Type: Observational
Study Design: N/A


Ages Eligible for Study:N/A
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

- INCLUSION CRITERIA: - Subjects, ages birth to 80 years old, known to have or suspected of having an inherited disorder of allergic inflammation or mast cell homeostasis or activation, will be eligible for enrollment. Because of the intensive time and labor required for research laboratory testing, subjects will be enrolled only if in the opinion of the investigator (based on discussions with the patient's private physician) there is a high index of suspicion of a genetic disease of allergic inflammation. Blood relatives of enrolled subjects will be eligible for enrollment. There will be no discrimination as to age, gender, race, or disability. - Subjects must have a health care provider outside of the NIH. - Subjects/guardians must be willing and able to give informed consent. - Subjects must agree to have their blood stored for future studies of the immune system and/or other medical conditions. - Women will be included in the study, including those who are lactating or may be pregnant. - Children will be included in the study. EXCLUSION CRITERIA: - The presence of an acquired abnormality of the immune system, such as cytotoxic chemotherapy or malignancy, may be grounds for possible exclusion if, in the opinion of the investigator, the presence of such a disease process would interfere with evaluation. - Subjects with a history of HIV or evidence of chronic Hepatitis B and/or C infection will be excluded.



  • National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland 20892 United States

Conditions related to this trial:

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.